Silence Therapeutics plc Share Price London S.E.
Stocks
SLN
GB00B9GTXM62
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 59Cr 80Cr 69Cr 65Cr 110.74Cr 7.66TCr 111.75Cr 774.45Cr 298.06Cr 3.89TCr 300.94Cr 294.36Cr 12TCr | P/E 2026 * |
-25x | P/E 2027 * | -20.1x |
|---|---|---|---|---|---|
| Enterprise Value | 46Cr 62Cr 53Cr 50Cr 86Cr 5.94TCr 87Cr 600.45Cr 231.09Cr 3.01TCr 233.32Cr 228.22Cr 9.57TCr | EV / Sales 2026 * |
1,424x | EV / Sales 2027 * | 557x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Silence Therapeutics plc
| 1 day | -0.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 01/12/2025 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 01/02/2022 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 21/06/2018 |
Iain Ross
CHM | Chairman | 72 | 01/01/2004 |
Tim McInerney
BRD | Director/Board Member | 65 | 05/05/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93% | -2.73% | - | - | 82Cr | |
| -0.56% | -8.08% | -3.88% | +10.58% | 4.64TCr | |
| -2.08% | -3.57% | +402.72% | +533.09% | 4.45TCr | |
| +0.12% | -5.27% | +39.94% | +20.50% | 4.23TCr | |
| -2.62% | -5.76% | +8.88% | +77.44% | 3.99TCr | |
| -1.26% | -3.37% | +11.87% | +40.55% | 3.28TCr | |
| +0.16% | -3.65% | - | - | 1.71TCr | |
| -0.54% | -1.72% | +22.34% | +115.10% | 1.64TCr | |
| -0.03% | -3.46% | +12.68% | +30.90% | 1.43TCr | |
| -1.92% | -6.94% | +78.12% | +36.68% | 1.33TCr | |
| Average | -0.97% | -4.30% | +71.58% | +108.10% | 2.97TCr | |
| Weighted average by Cap. | -1.09% | -4.54% | +87.11% | +129.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3L 4L 4L 4L 6L 4.17Cr 6L 42.15L 16.22L 2.12Cr 16.38L 16.02L 6.72Cr | 8L 10.15L 9L 8L 14.03L 9.71Cr 14.16L 98.12L 37.76L 4.92Cr 38.13L 37.29L 16Cr |
| Net income | -4.21Cr -5.7Cr -4.9Cr -4.63Cr -7.88Cr -544.97Cr -7.95Cr -55Cr -21Cr -276.42Cr -21Cr -21Cr -877.99Cr | -7.1Cr -9.61Cr -8.26Cr -7.79Cr -13Cr -918.43Cr -13Cr -93Cr -36Cr -465.84Cr -36Cr -35Cr -1.48TCr |
| Net Debt | -13Cr -18Cr -15Cr -15Cr -25Cr -1.72TCr -25Cr -174Cr -67Cr -873.12Cr -68Cr -66Cr -2.77TCr | -17Cr -24Cr -20Cr -19Cr -33Cr -2.25TCr -33Cr -227.52Cr -88Cr -1.14TCr -88Cr -86Cr -3.63TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
